CEL SCI CORP Q2 2025: Assets $63.8M, Liabilities $84.4M

Ticker: CVM · Form: 10-Q · Filed: May 14, 2025 · CIK: 725363

Sentiment: bearish

Topics: financials, balance-sheet, cash-flow

TL;DR

CEL SCI CORP Q2 2025: Liabilities > Assets. Cash burn continues.

AI Summary

CEL SCI CORP filed its Q2 2025 10-Q report on May 14, 2025, for the period ending March 31, 2025. The company reported total assets of $63.79 million and total liabilities of $84.35 million. Significant cash outflows were noted, with $200,000 in cash used for investing activities and $900,000 for financing activities during the six months ended March 31, 2025.

Why It Matters

The filing reveals CEL SCI CORP's financial position as of Q2 2025, showing liabilities exceeding assets, which could indicate financial strain.

Risk Assessment

Risk Level: high — The company's liabilities ($84.35 million) exceed its assets ($63.79 million), suggesting a negative net worth and potential financial instability.

Key Numbers

Key Players & Entities

FAQ

What is CEL SCI CORP's net worth as of March 31, 2025?

CEL SCI CORP's net worth is negative, with total liabilities of $84.35 million exceeding total assets of $63.79 million.

How much cash did CEL SCI CORP use in its investing activities during the first six months of fiscal year 2025?

CEL SCI CORP used $200,000 in cash for investing activities during the six months ended March 31, 2025.

What were the financing activities cash outflows for CEL SCI CORP in the first half of fiscal year 2025?

CEL SCI CORP had cash outflows of $900,000 for financing activities during the six months ended March 31, 2025.

When is CEL SCI CORP's fiscal year end?

CEL SCI CORP's fiscal year ends on September 30.

What is the SIC code for CEL SCI CORP?

The Standard Industrial Classification (SIC) code for CEL SCI CORP is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding CEL SCI CORP (CVM).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing